OncoZenge – Research analysis on the dental care opportunity for BupiZenge™
Igår, 15:06
Impala Nordic publishes a research analysis of OncoZenge AB (publ) ("OncoZenge" or the "Company") examining where a lozenge-based, needle-free local anaesthetic could fit into everyday dental pain management, and which subsegments appear most relevant. The analysis assesses three distinct use cases: scaling and root planing, postoperative pain following dental procedures, and recurrent aphthous stomatitis.
It has been developed in dialogue with two dental clinical experts. Dr Paul Murtagh is an experienced dentist and clinic founder with international clinical experience across Ireland, the UK, Sweden and the United States. He has been recognised for research in dental materials, including an award from the International Association for Dental Research, has completed advanced training in implant dentistry, and has founded and operated multiple dental clinics in Ireland and Sweden. He has also worked as a clinical supervisor within the Swedish Public Dental Service. Dr Sayf Hosamaldin is a dentist undertaking specialist training in maxillofacial surgery while pursuing medical studies at Linköping University, is research-active across two university hospitals, and serves as Chair of the Junior Section of the Swedish Association for Maxillofacial Surgery. Their input shapes the clinical assessment of where a locally acting lozenge could realistically be used, and where it could not.
Our conclusion is that dental care is a credible long-term expansion area for BupiZenge™ rather than a near-term value driver. None of the ongoing rights issue is earmarked for dental development, and on the current plan a dental indication would be a partnering or licensing opportunity that sits behind the Phase III readout in sequence.
Read the full research report here
For additional information, please contact:
Ylber Rexhepi, CEO Impala Nordic
ylber@impalanordic.se
About Impala Nordic
Impala Nordic provides equity research, coverage, and comprehensive investor relations (IR) services. The portfolio includes listed small-cap companies, where Impala Nordic acts as a communicative bridge between the companies and investors.
The material produced by Impala Nordic is independent but sponsored. This means that Impala Nordic has received payment from the client to produce the analysis and coverage. The client has not been able to influence Impala Nordic’s opinions expressed in the material.
Bifogade filer
Ämnen i artikeln
OncoZenge – Research analysis on the dental care opportunity for BupiZenge™
Igår, 15:06
Impala Nordic publishes a research analysis of OncoZenge AB (publ) ("OncoZenge" or the "Company") examining where a lozenge-based, needle-free local anaesthetic could fit into everyday dental pain management, and which subsegments appear most relevant. The analysis assesses three distinct use cases: scaling and root planing, postoperative pain following dental procedures, and recurrent aphthous stomatitis.
It has been developed in dialogue with two dental clinical experts. Dr Paul Murtagh is an experienced dentist and clinic founder with international clinical experience across Ireland, the UK, Sweden and the United States. He has been recognised for research in dental materials, including an award from the International Association for Dental Research, has completed advanced training in implant dentistry, and has founded and operated multiple dental clinics in Ireland and Sweden. He has also worked as a clinical supervisor within the Swedish Public Dental Service. Dr Sayf Hosamaldin is a dentist undertaking specialist training in maxillofacial surgery while pursuing medical studies at Linköping University, is research-active across two university hospitals, and serves as Chair of the Junior Section of the Swedish Association for Maxillofacial Surgery. Their input shapes the clinical assessment of where a locally acting lozenge could realistically be used, and where it could not.
Our conclusion is that dental care is a credible long-term expansion area for BupiZenge™ rather than a near-term value driver. None of the ongoing rights issue is earmarked for dental development, and on the current plan a dental indication would be a partnering or licensing opportunity that sits behind the Phase III readout in sequence.
Read the full research report here
For additional information, please contact:
Ylber Rexhepi, CEO Impala Nordic
ylber@impalanordic.se
About Impala Nordic
Impala Nordic provides equity research, coverage, and comprehensive investor relations (IR) services. The portfolio includes listed small-cap companies, where Impala Nordic acts as a communicative bridge between the companies and investors.
The material produced by Impala Nordic is independent but sponsored. This means that Impala Nordic has received payment from the client to produce the analysis and coverage. The client has not been able to influence Impala Nordic’s opinions expressed in the material.
Bifogade filer
Ämnen i artikeln
SBB
Valet
SBB
Valet
Marknadsöversikt
1 DAG %
Senast
1 mån
